First Trust Advisors LP reduced its stake in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 39.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 414,338 shares of the company’s stock after selling 265,512 shares during the quarter. First Trust Advisors LP owned 0.07% of Express Scripts worth $31,991,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Kaizen Advisory LLC grew its stake in shares of Express Scripts by 147.6% in the second quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock worth $104,000 after purchasing an additional 800 shares during the last quarter. Wealthcare Advisory Partners LLC grew its stake in shares of Express Scripts by 364.7% in the first quarter. Wealthcare Advisory Partners LLC now owns 1,529 shares of the company’s stock worth $106,000 after purchasing an additional 1,200 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Express Scripts by 3,048.1% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,637 shares of the company’s stock worth $126,000 after purchasing an additional 1,585 shares during the last quarter. ClariVest Asset Management LLC grew its stake in shares of Express Scripts by 31,700.0% in the first quarter. ClariVest Asset Management LLC now owns 2,226 shares of the company’s stock worth $153,000 after purchasing an additional 2,219 shares during the last quarter. Finally, CKW Financial Group bought a new stake in shares of Express Scripts in the second quarter worth about $154,000. 84.52% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Christine Houston sold 10,000 shares of Express Scripts stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $82.28, for a total transaction of $822,800.00. Following the completion of the transaction, the insider now directly owns 108,010 shares in the company, valued at $8,887,062.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.79% of the stock is currently owned by company insiders.
Express Scripts opened at $83.64 on Monday, Marketbeat Ratings reports. Express Scripts Holding Co has a 52-week low of $55.80 and a 52-week high of $85.42. The company has a market cap of $47.02 billion, a PE ratio of 10.39, a price-to-earnings-growth ratio of 1.05 and a beta of 0.95. The company has a quick ratio of 0.59, a current ratio of 0.71 and a debt-to-equity ratio of 0.69.
Express Scripts (NASDAQ:ESRX) last released its earnings results on Wednesday, August 1st. The company reported $2.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.20 by $0.02. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. The firm had revenue of $25.64 billion during the quarter, compared to analyst estimates of $25.43 billion. During the same period last year, the business earned $1.73 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. sell-side analysts predict that Express Scripts Holding Co will post 9.07 EPS for the current year.
Express Scripts Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.